Clinical impact of renal dysfunction in heart failure

Reviews in Cardiovascular Medicine

Volumn 12, Issue 4, 2011, Pages 186-199

  Palazzuoli, Alberto ^a   Beltrami, Matteo ^a   Nodari, Savina ^b   McCullough, Peter A ^c   Ronco, Claudio ^d  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c St John Providence Health System   (United States)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Cardiorenal syndrome; Chronic kidney disease; Heart failure; Mortality

Indexed keywords

ACUTE DISEASE; ACUTE HEART FAILURE; ADRENERGIC SYSTEM; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART FAILURE; HEART OUTPUT; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PERFUSION; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PERFUSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; CLINICAL TRIALS AS TOPIC; HUMANS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84855564066     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0581     Document Type: Review

References (66)

1. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systemic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110:378-384. (Pubitemid 32245810)
2. McCullough PA, Li S, Jurkovitz CT, et al KEEP Investigators. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008;156:277-283.
3. Dickstein K, Cohen-Solal A, Filippatos G, et al ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29: 2388-2442.
4. Heart Failure Society of America. Conceptualization and working definition of heart failure. J Card Fail. 2006;12:e10-e11.
5. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif. 2010;29:300-307.
6. Bagshaw SM, Cruz DN, Aspromonte N, et al Acute Dialysis Quality Initiative Consensus Group. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant. 2010;25:1406-1416.
7. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13-25. (Pubitemid 36356697)
8. Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol. 2008;127:228-232. (Pubitemid 351787799)
9. Cowie MR, Komajda M, Murray-Thomas T, et al; for the POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the Prospective Outcomes Study in Heart Failure (POSH). Eur Heart J. 2006;27:1216-1222.
10. Rusinaru D, Buiciuc O, Houpe D, Tribouilloy C. Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. Int J Cardiol. 2011;147:278-282.
11. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268-1274. (Pubitemid 351400890)
12. Heywood JT, Fonarow GC, Costanzo MR, et al ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422-430.
13. Klein L, Massie BM, Leimberger JD, et al; OPTIME-CHF Investigators. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1:25-33.
14. Smith GL, Shlipak MG, Havranek EP, et al. Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med. 2006;166:1134-1142. (Pubitemid 43765186)
15. Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail. 2008;1:2-5.
16. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
17. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: a systematic review and meta-analysis. J Card Fail. 2007;13:599-608. (Pubitemid 47513536)
18. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689. (Pubitemid 30167025)
19. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138:849-855. (Pubitemid 29523271)
20. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
21. Hillege HL, Nitsch D, Pfeffer MA, et al; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal Function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
22. Anand IS, Bishu K, Rector TS, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120:1577-1584.
23. Chonchol M, Goldenberg I, Moss AJ, et al. Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol. 2007;27:7-14. (Pubitemid 46364535)
24. Saxon LA, Bristow MR, Bohemer J, et al. Predictors of sudden cardiac death and appropriate shock in the comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION). Circulation. 2006;114:2766-2772. (Pubitemid 46018278)
25. Goldenberg I, Moss AJ, McNitt S, et al Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2006;98:485-490. (Pubitemid 44162874)
26. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;043:61-67. (Pubitemid 38045917)
27. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-1996.
28. Tsagalis G, Bakirtzi N, Spengos K, et al. Long-term prognosis of combined chronic heart failure and chronic renal dysfunction after acute stroke. Eur J Heart Fail. 2010;12:849-854.
29. Lamb EJ, Tomson CR, Roderick PJ; Clinical Sciences Reviews Committee of the Association for Clinical Biochemistry. Estimating kidney function in adults using formulae. Ann Clin Biochem. 2005;42:321-345. (Pubitemid 41354394)
30. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16:1404-1412. (Pubitemid 41716524)
31. Tidman M, Sjöström P, Jones I. A comparison of GFR estimating formulae based upon s- cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant. 2008;23: 154-160. (Pubitemid 351767410)
32. Jackson CE, Solomon SD, Gerstein HC, et al CHARM Investigators and Committees. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;347:543-550.
33. Hillege HL, Fidler V, Diercks GF, et al Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
34. Wagener G, Gubitosa G, Wang S, et al. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis. 2008;52:425-433.
35. Yndestad A, Landrø L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30:1229-1236.
36. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16:49-54.
37. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;36:S75-S88.
38. Packer M. The neurohormonal hypothesis: a theory to explain heart disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
39. Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001;110(suppl 7A):37S-46S.
40. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009;54:375-385.
41. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006;119(12 suppl 1):S11-S16. (Pubitemid 44738815)
42. Metra M, Dei Cas L, Bristow MR. The pathophysiology of acute heart failure-it is a lot about fluid accumulation. Am Heart J. 2008;155:1-5. (Pubitemid 350234786)
43. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure - redistribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10:165-169. (Pubitemid 351222743)
44. Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin J Med. 2006;73(suppl 3):S19-S23.
45. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97. (Pubitemid 46127306)
46. Petrie CJ, Mark PB, Weir RA. Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review. Int J Cardiol. 2008;128:154-165.
47. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006;47:1-8. (Pubitemid 43005157)
48. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988;1:1033-1035.
49. Jessup M, Costanzo MR. The cardiorenal syndrome. Do we need a change of strategy or a change of tactics? J Am Coll Cardiol. 2009;53:597-599.
50. Ramirez G, Brueggemeyer CD, Newton JL. Cardiac arrhythmias in haemodialysis in chronic renal failure patients. Nephron. 1984; 36:212-218. (Pubitemid 14192559)
51. Gruppo Emodialisi e Patologie Cardiovasculari. Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients. Lancet. 1988;2:305-309.
52. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int. 2004;65:2380-2389. (Pubitemid 38670024)
53. Myerburg RJ, Castellanos A. Emerging paradigms of the epidemiology and demographics of sudden cardiac arrest. Heart Rhythm. 2006;3:235-239. (Pubitemid 43150000)
54. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169. (Pubitemid 37337595)
55. Mangrum JM, Lin D, Dimarco JP, et al. Prognostic value of LV systolic function in haemodialysis patients. Heart Rhythm. 2006; 3(suppl):S154.
56. Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol. 2000;11:912-916. (Pubitemid 30241725)
57. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489-495. (Pubitemid 41725146)
58. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377-1384. (Pubitemid 44427424)
59. Costanzo MR, Saltzberg MT, Jessup M, et al Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail. 2010;16:277-284.
60. Heywood JT, Fonarow GC, Yancy CW, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol 2010;105:1140-1146.
61. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724-731. (Pubitemid 39056273)
62. Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients. Beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2001;37:407-411.
63. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-1444. (Pubitemid 36543357)
64. Cotter G, Dittrich HC, Weatherley BD, et al Protect Steering Committee, Investigators, and Coordinators. The PROTECT Pilot Study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008;14: 631-640.
65. Gheorghiade M, Gottlieb SS, Udelson JE, et al; Tolvaptan investigators. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97:1064-1067.
66. O'Connor CM, Miller AB, Blair JE, et al; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159:841-849.e1.